Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232343 | 0.83 | AVPR1A (0.57) | MAPK1AVPR1ASCD5CYP11B2 | |
| SCHEMBL29561744 | 0.79 | OTUD7B (0.53) | OTUD7BMAPK1USP30SCD5CYP11B2 | |
| SCHEMBL20721891 | 0.79 | OTUD7B (0.53) | OTUD7BMAPK1USP30SCD5CYP11B2 | |
| SCHEMBL27245066 | 0.78 | OTUD7B (0.43) | OTUD7BMAPK1AVPR1ANR1H2RXRA | |
| SCHEMBL30890677 | 0.78 | OTUD7B (0.43) | OTUD7BMAPK1AVPR1ANR1H2RXRA | |
| SCHEMBL20721877 | 0.77 | OTUD7B (0.57) | OTUD7BMAPK1USP30SCD5CYP11B2 | |
| SCHEMBL3231066 | 0.77 | AVPR1A (0.54) | MAPK1AVPR1ASCD5CYP11B2 | |
| SCHEMBL30992215 | 0.77 | OTUD7B (0.42) | OTUD7BMAPK1AVPR1ANR1H2RXRA | |
| SCHEMBL2604293 | 0.77 | MAPK1 (0.52) | OTUD7BMAPK1USP30NR1H2RXRA | |
| SCHEMBL3184731 | 0.77 | MAPK1 (0.52) | OTUD7BMAPK1USP30NR1H2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4067355-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2022-10-05 | — | — | EP | disclosed |
| EP-3423454-B1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-25 | — | — | EP | disclosed |
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-08-06 | — | — | US | disclosed |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| EP-3423454-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106315-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885MAPK1 3103/4885AVPR1A 4084/4885 |
| US-20200247803-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885MAPK1 3103/4885AVPR1A 4084/4885 |
| US-10654853-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885MAPK1 3103/4885AVPR1A 4084/4885 |
| US-20190048008-A1 | SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885MAPK1 3103/4885AVPR1A 4084/4885 |
| US-11236092-B2 | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors | OTUB1, UBE2E1, RCE1 | OTUD7B 25/4885MAPK1 3103/4885AVPR1A 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.